Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GCK | P35557 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183994 | 0.95 | LMNA (0.70) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL391547 | 0.92 | MEN1 (0.71) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL862870 | 0.89 | MEN1 (0.93) | MEN1KMT2ANR4A2NR4A1NR4A3 | |
| SCHEMBL14345811 | 0.89 | LMNA (0.62) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL6843288 | 0.89 | MRGPRX4 (0.66) | MEN1KMT2ANR4A2SMN1; SMN2MRGPRX4 | |
| SCHEMBL29788280 | 0.88 | LMNA (0.65) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL29475634 | 0.88 | LMNA (0.69) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL340311 | 0.88 | LMNA (0.65) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL90412 | 0.88 | LMNA (0.69) | MEN1KMT2ALMNAHPGDNR4A2 | |
| SCHEMBL7362723 | 0.87 | HPGD (0.63) | MEN1KMT2ALMNAHPGDNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| WO-2016001452-A1 | COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED | Universität Zürich (CH) | 2016-01-07 | — | — | WO | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| US-20120277208-A1 | BENZAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-11-01 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2511265-A1 | BENZAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-10-17 | — | — | EP | disclosed |
| CN-102656141-A | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| CN-102656149-A | Benzamide compounds | ASTELLAS PHARMA INC | 2012-09-05 | — | — | CN | disclosed |
| US-8076359-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-12-13 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| CN-1161694-A | Nucleoside derivatives and process for preparing same | CHONG KUN DANG CORP (KR) | 1997-10-08 | — | — | CN | disclosed |
| US-4018825-A | BRONCHODILATORS | WARNER-LAMBERT COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | MEN1 3945/4885KMT2A 1493/4885LMNA 2556/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | MEN1 586/4885KMT2A 300/4885LMNA 1062/4885 |
| US-20120277208-A1 | BENZAMIDE COMPOUND | GK, GCKR, GPR119 | MEN1 2957/4885KMT2A 254/4885LMNA 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.